Response to First-line Recurrence Treatment Influences Survival in Hormone Receptor-positive, HER2-negative Breast Cancer: A Multicenter Study-Reference-Cited by-同舟云学术

Response to First-line Recurrence Treatment Influences Survival in Hormone Receptor-positive, HER2-negative Breast Cancer: A Multicenter Study

Published:2018-12-26 Issue:1 Volume:33 Page:281-287
ISSN:0258-851X
Container-title:In Vivo
language:en
Short-container-title:In Vivo

Author:

YAMAMURA JUN,KAMIGAKI SHUNJI,TSUJIE MASAKI,FUJITA JUNYA,OSATO HIROKI,HIGASHI CHIHIRO,KANAIZUMI HIROFUMI,TANAKA YUMIKO,HAMADA MIKA,SHINZAKI WATARU,HASHIMOTO YUKIHIKO,KOMOIKE YOSHIFUMI

Publisher

Anticancer Research USA Inc.

Subject

Pharmacology,General Biochemistry, Genetics and Molecular Biology,Cancer Research

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy;The Breast;2024-02

2. Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer;Breast Cancer Research and Treatment;2022-12-21

3. Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study;Japanese Journal of Clinical Oncology;2022-03-16

4. Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors;Clinical Breast Cancer;2021-12

5. Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study;Scientific Reports;2021-11-02